NKTR - Nektar Therapeutics Stock Price, Fair Value and News

1.57USD-0.10 (-5.99%)Market Closed

Market Summary

USD1.57-0.10

Market Closed

-5.99%

NKTR Stock Price

View Fullscreen

NKTR RSI Chart

NKTR Valuation

Market Cap

288.3M

Price/Earnings (Trailing)

-1.05

Price/Sales (Trailing)

3.2

EV/EBITDA

-0.94

Price/Free Cashflow

-1.49

NKTR Price/Sales (Trailing)

NKTR Profitability

EBT Margin

-306.54%

Return on Equity

-210.58%

Return on Assets

-69.3%

Free Cashflow Yield

-67.11%

NKTR Fundamentals

NKTR Revenue

Revenue (TTM)

90.1M

Rev. Growth (Yr)

8.45%

Rev. Growth (Qtr)

-1.07%

NKTR Earnings

Earnings (TTM)

-275.8M

Earnings Growth (Yr)

26.64%

Earnings Growth (Qtr)

7.7%

Breaking Down NKTR Revenue

Last 7 days

19.9%

Last 30 days

82.6%

Last 90 days

201.9%

Trailing 12 Months

69.7%

How does NKTR drawdown profile look like?

NKTR Financial Health

Current Ratio

6.45

NKTR Investor Care

Buy Backs (1Y)

2.97%

Diluted EPS (TTM)

-1.46

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	88.8M	87.7M	88.3M	90.1M
2022	103.1M	96.3M	95.0M	92.1M
2021	126.0M	105.5M	100.4M	101.9M
2020	137.0M	162.5M	163.3M	152.9M
2019	1.2B	119.1M	120.6M	114.6M
2018	529.1M	750.5M	971.9M	1.2B
2017	131.3M	133.1M	249.7M	307.7M
2016	180.9M	191.0M	167.4M	165.4M
2015	289.7M	283.9M	211.0M	230.8M
2014	145.7M	140.3M	212.3M	200.7M
2013	86.2M	96.4M	138.9M	148.9M
2012	78.1M	84.5M	75.8M	81.2M
2011	137.1M	111.9M	101.0M	71.5M
2010	93.7M	115.5M	137.3M	159.0M
2009	0	0	0	71.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Nektar Therapeutics

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 20, 2024	robin howard w	sold	-13,622	0.68	-20,033	president & ceo
Feb 20, 2024	wilson mark andrew	sold	-5,172	0.68	-7,606	chief legal officer
Feb 20, 2024	zalevsky jonathan	sold	-6,129	0.68	-9,014	chief r&d officer
Nov 17, 2023	zalevsky jonathan	sold	-4,726	0.49	-9,646	chief r&d officer
Nov 17, 2023	robin howard w	sold	-9,739	0.49	-19,877	president & ceo
Nov 17, 2023	wilson mark andrew	sold	-3,517	0.49	-7,179	chief legal officer
Sep 18, 2023	ajer jeffrey robert	sold	-3,007	0.69	-4,359	-
Sep 18, 2023	curet myriam	sold	-3,007	0.69	-4,359	-
Aug 16, 2023	robin howard w	sold	-15,598	0.78	-19,998	president & ceo
Aug 16, 2023	wilson mark andrew	sold	-5,632	0.78	-7,221	chief legal officer

Which funds bought or sold NKTR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 10, 2024	US Asset Management LLC	unchanged	-	14,000	36,000	0.03%
Apr 10, 2024	Founders Capital Management	unchanged	-	258	654	-%
Apr 05, 2024	Compass Wealth Management LLC	unchanged	-	739	1,869	-%
Apr 05, 2024	CWM, LLC	unchanged	-	-	-	-%
Apr 03, 2024	Versant Capital Management, Inc	unchanged	-	63.00	158	-%
Apr 03, 2024	WealthCollab, LLC	new	-	170	170	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	57.00	57.00	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-0.15	-379,396	6,804,220	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	68.32	364,810	976,172	-%
Feb 26, 2024	TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY	sold off	-100	-37,000	-	-%

Are Funds Buying or Selling NKTR?

Are funds buying NKTR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NKTR

No. of Funds

Unveiling Nektar Therapeutics's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 15, 2024	tcg crossover gp ii, llc	9.9%	20,046,350	SC 13G
Feb 14, 2024	deep track capital, lp	9.65%	18,400,000	SC 13G/A
Feb 14, 2024	citadel advisors llc	3.0%	6	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	0%	0	SC 13G/A
Feb 13, 2024	vanguard group inc	6.31%	12,042,873	SC 13G/A
Aug 17, 2023	ra capital management, l.p.	9.8%	18,700,000	SC 13G
Jul 10, 2023	invesco ltd.	2.9%	5,535,430	SC 13G/A
Jul 10, 2023	vanguard group inc	6.37%	12,056,187	SC 13G/A
Jul 07, 2023	blackrock inc.	4.5%	8,604,322	SC 13G/A
Jul 07, 2023	primecap management co/ca/	4.31%	8,149,876	SC 13G/A

Recent SEC filings of Nektar Therapeutics

View All Filings

Date Filed	Form Type	Document
Mar 19, 2024	D	D
Mar 15, 2024	SC 13G	Major Ownership Report
Mar 14, 2024	3	Insider Trading
Mar 05, 2024	10-K	Annual Report
Mar 04, 2024	8-K	Current Report
Mar 04, 2024	8-K	Current Report
Feb 22, 2024	4	Insider Trading
Feb 22, 2024	4	Insider Trading
Feb 22, 2024	4	Insider Trading
Feb 20, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Nektar Therapeutics)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	0.01%	-33.89%	-8.42	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.06%	-27.57%	-42.25	10.17	76.23%	61.08%
BMRN	17.3B	2.4B	9.12%	-7.56%	103	7.14	15.42%	18.43%
INCY	12.0B	3.7B	-8.48%	-28.30%	20.07	3.25	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.27%	-36.41%	-11.74	15.65	425.83%	18.94%
BBIO	4.5B	-	-6.46%	74.90%	-6.94	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-9.62%	-0.34%	-13.52	11.95	440.80%	-27.84%
ARWR	3.0B	240.7M	-15.06%	-21.14%	-10.03	12.36	-1.03%	-92.09%
ACAD	2.8B	726.4M	-8.60%	-6.11%	-45.41	3.83	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.17%	-12.95%	25.42	4.56	85.90%	-14.05%
NVAX	576.6M	983.7M	-22.12%	-55.02%	-1.06	0.59	-50.36%	17.16%
CRBP	448.6M	881.7K	-2.13%	345.78%	-10.06	466.16	-77.61%	-5.33%
INO	256.8M	4.9M	2.33%	7.75%	-1.9	52.78	-54.97%	51.72%
IBIO	6.7M	2.1M	82.86%	81.13%	-0.25	2.14	-13.45%	66.37%

Nektar Therapeutics News

Latest updates

Nektar Therapeutics Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-1.1%	23,885,000	24,144,000	20,499,000	21,594,000	22,023,000	23,625,000	21,585,000	24,822,000	25,009,000	24,921,000	28,330,000	23,647,000	23,462,000	30,033,000	48,847,000	50,573,000	33,862,000	29,218,000	23,315,000	28,222,000	39,826,000
Costs and Expenses	-16.8%	57,396,000	69,008,000	71,098,000	156,304,000	74,492,000	77,926,000	174,421,000	141,382,000	137,919,000	138,517,000	138,535,000	133,039,000	134,183,000	133,083,000	126,556,000	184,204,000	143,500,000	127,958,000	134,285,000	148,909,000	140,121,000
S&GA Expenses	-18.1%	17,320,000	21,147,000	17,869,000	21,081,000	21,939,000	22,534,000	20,521,000	27,339,000	32,142,000	29,468,000	29,555,000	31,679,000	27,136,000	26,982,000	24,347,000	26,217,000	27,142,000	23,983,000	22,581,000	25,006,000	23,777,000
R&D Expenses	24.4%	29,942,000	24,070,000	29,681,000	30,469,000	34,740,000	33,590,000	42,740,000	107,253,000	99,614,000	103,738,000	101,313,000	95,604,000	102,724,000	100,531,000	96,436,000	108,987,000	110,369,000	99,048,000	106,686,000	118,463,000	108,883,000
EBITDA Margin	6.6%	-2.98	-3.19	-3.35	-4.51	-3.82	-4.64	-5.30	-4.62	-5.00	-4.79	-4.36	-3.29	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	647,000	6,204,000	5,428,000	5,425,000	5,231,000	5,226,000	5,415,000
Income Taxes	52.5%	-29,000	-61,000	-47,000	-63,000	3,144,000	-155,000	100,000	126,000	-4,000	112,000	357,000	92,000	128,000	21,000	144,000	200,000	278,000	99,000	99,000	137,000	-1,838,000
Earnings Before Taxes	8.3%	-42,108,000	-45,898,000	-51,169,000	-137,081,000	-56,544,000	-59,204,000	-158,968,000	-90,267,000	-145,649,000	-129,594,000	-125,162,000	-122,875,000	-117,075,000	-108,565,000	-79,856,000	-138,451,000	-111,886,000	-98,486,000	-110,187,000	-119,495,000	-100,050,000
EBT Margin	6.9%	-3.07	-3.29	-3.46	-4.64	-3.96	-4.78	-5.44	-4.76	-5.13	-4.93	-4.49	-3.40	-	-	-	-	-	-	-	-	-
Net Income	7.7%	-42,307,500	-45,837,000	-51,891,000	-135,792,000	-57,671,000	-59,049,000	-160,727,000	-92,768,000	-145,645,000	-129,706,000	-125,798,000	-123,793,000	-117,203,000	-108,586,000	-80,000,000	-138,651,000	-112,164,000	-98,585,000	-110,286,000	-119,632,000	-98,212,000
Net Income Margin	7.2%	-3.06	-3.30	-3.47	-4.65	-4.02	-4.82	-5.49	-4.79	-5.15	-4.95	-4.51	-3.41	-	-	-	-	-	-	-	-	-
Free Cashflow	-12.2%	-47,284,000	-42,154,000	-51,685,000	-52,348,000	-58,215,000	-83,068,000	-75,773,000	-92,627,000	-157,434,000	-104,072,000	-86,182,000	-79,961,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-10.0%	398	442	494	562	711	781	862	1,024	1,117	1,277	1,371	1,457	1,539	1,509	1,595	1,888	1,977	2,088	2,100	2,166	2,150
Current Assets	-17.1%	331	399	441	491	546	599	666	733	796	986	1,056	1,099	1,138	1,044	1,152	1,429	1,422	1,579	1,597	1,490	1,438
Cash Equivalents	-45.7%	35.00	65.00	51.00	77.00	88.00	106	78.00	68.00	25.00	54.00	152	150	199	56.00	58.00	227	96.00	81.00	85.00	107	195
Inventory	6.4%	16.00	15.00	21.00	20.00	19.00	19.00	17.00	15.00	16.00	15.00	15.00	17.00	15.00	13.00	13.00	14.00	13.00	14.00	13.00	12.00	11.00
Net PPE	-5.5%	19.00	20.00	23.00	27.00	32.00	37.00	40.00	61.00	61.00	59.00	59.00	59.00	60.00	60.00	61.00	62.00	66.00	65.00	65.00	58.00	49.00
Goodwill	-	-	-	-	-	77.00	77.00	77.00	77.00	77.00	77.00	77.00	77.00	77.00	77.00	77.00	77.00	77.00	77.00	77.00	77.00	77.00
Liabilities	-5.6%	267	283	297	321	344	369	403	416	438	476	466	462	461	338	339	592	572	600	542	533	433
Current Liabilities	-1.6%	51.00	52.00	51.00	60.00	68.00	84.00	105	105	85.00	140	131	124	116	127	124	377	354	125	113	100	82.00
Shareholder's Equity	-17.8%	131	159	197	241	367	412	459	608	680	802	905	995	1,077	1,171	1,256	1,296	1,405	1,489	1,557	1,634	1,718
Retained Earnings	-1.2%	-3,477	-3,435	-3,389	-3,338	-3,201	-3,141	-3,082	-2,923	-2,832	-2,687	-2,557	-2,432	-2,309	-2,191	-2,083	-2,003	-1,864	-1,751	-1,652	-1,542	-1,424
Additional Paid-In Capital	0.2%	3,608	3,601	3,593	3,585	3,575	3,562	3,549	3,538	3,517	3,492	3,466	3,430	3,389	3,364	3,339	3,307	3,271	3,241	3,210	3,179	3,148
Accumulated Depreciation	-1.5%	87.00	88.00	108	111	125	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	0.3%	191	191	190	189	189	188	186	186	185	184	183	181	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	704	-	-	-	3,100	-	-	-	4,100	-	-	-	6,184	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-11.7%	-47,047	-42,121	-51,523	-51,915	-57,703	-82,887	-74,993	-88,424	-151,538	-101,136	-82,901	-77,085	-98,634	-52,675	-83,903	-78,075	-125,223	-68,641	-53,922	-80,895	-117,550
Share Based Compensation	-11.0%	7,254	8,149	7,966	10,019	12,738	12,518	11,103	20,961	22,405	24,657	23,714	23,898	21,987	23,667	23,371	25,236	25,008	24,880	24,522	25,385	24,206
Cashflow From Investing	-69.2%	17,383	56,412	25,171	40,598	40,014	111,395	84,148	130,278	120,197	-830	72,952	10,458	92,740	48,668	157,038	197,767	135,481	58,253	25,290	-12,138	87,540
Cashflow From Financing	-	12.00	-	18.00	-	103	-	467	938	2,552	3,663	12,167	17,856	148,995	1,531	-241,957	11,077	4,906	6,249	7,306	4,894	2,668

NKTR Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue	$ 90,122	$ 92,055	$ 101,907
Operating costs and expenses:
Cost of goods sold	33,768	21,635	24,897
Research and development	114,162	218,323	400,269
General and administrative	77,417	92,333	122,844
Restructuring, impairment and costs of terminated program	51,958	135,930	0
Impairment of goodwill	76,501	0	0
Total operating costs and expenses	353,806	468,221	548,010
Loss from operations	(263,684)	(376,166)	(446,103)
Non-operating income (expense):
Change in fair value of development derivative liability	0	33,427	(8,023)
Non-cash interest expense on liabilities related to the sales of future royalties	(25,334)	(28,911)	(47,313)
Loss on revaluation of liability related to the sale of future royalties	0	0	(24,410)
Interest income	19,009	6,783	2,731
Other income (expense), net	(6,247)	(116)	(162)
Total non-operating income (expense), net	(12,572)	11,183	(77,177)
Loss before provision for income taxes	(276,256)	(364,983)	(523,280)
Provision (benefit) for income taxes	(200)	3,215	557
Net loss	$ (276,056)	$ (368,198)	$ (523,837)
Basic net loss per share (in dollars per share)	$ (1.45)	$ (1.97)	$ (2.86)
Diluted net loss per share (in dollars per share)	$ (1.45)	$ (1.97)	$ (2.86)
Weighted average shares outstanding used in computing basic net loss per share (in shares)	190,001	187,138	183,298
Weighted average shares outstanding used in computing diluted net loss per share (in shares)	190,001	187,138	183,298
Product sales
Revenue:
Total revenue	$ 20,681	$ 20,348	$ 23,725
Non-cash royalty revenue related to the sales of future royalties
Revenue:
Total revenue	68,921	69,794	77,746
License, collaboration and other revenue
Revenue:
Total revenue	$ 520	$ 1,913	$ 436

NKTR Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 35,277	$ 88,227
Short-term investments	268,339	416,750
Accounts receivable	1,205	5,981
Inventory	16,101	19,202
Other current assets	9,779	15,808
Total current assets	330,701	545,968
Long-term investments	25,825	0
Property, plant and equipment, net	18,856	32,451
Operating lease right-of-use assets	18,007	53,435
Goodwill	0	76,501
Other assets	4,644	2,245
Total assets	398,033	710,600
Current liabilities:
Accounts payable	9,848	12,980
Accrued expenses	22,162	36,557
Operating lease liabilities, current portion	19,259	18,667
Total current liabilities	51,269	68,204
Operating lease liabilities, less current portion	98,517	112,829
Liabilities related to the sales of future royalties, net	112,625	155,378
Other long-term liabilities	4,635	7,551
Total liabilities	267,046	343,962
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at December 31, 2023 or 2022	0	0
Common stock, $0.0001 par value; 300,000 shares authorized; 191,384 shares and 188,560 shares issued and outstanding at December 31, 2023 and 2022, respectively	19	19
Capital in excess of par value	3,608,137	3,574,719
Accumulated other comprehensive income (loss)	80	(6,907)
Accumulated deficit	(3,477,249)	(3,201,193)
Total stockholders’ equity	130,987	366,638
Total liabilities and stockholders’ equity	$ 398,033	$ 710,600

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

CEO	Mr. Howard W. Robin
WEBSITE	nektar.com
INDUSTRY	Biotechnology
EMPLOYEES	216

Nektar Therapeutics Frequently Asked Questions

What is the ticker symbol for Nektar Therapeutics? What does NKTR stand for in stocks?

NKTR is the stock ticker symbol of Nektar Therapeutics. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nektar Therapeutics (NKTR)?

As of Mon Apr 15 2024, market cap of Nektar Therapeutics is 288.28 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NKTR stock?

You can check NKTR's fair value in chart for subscribers.

What is the fair value of NKTR stock?

You can check NKTR's fair value in chart for subscribers. The fair value of Nektar Therapeutics is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Nektar Therapeutics is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NKTR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Nektar Therapeutics a good stock to buy?

The fair value guage provides a quick view whether NKTR is over valued or under valued. Whether Nektar Therapeutics is cheap or expensive depends on the assumptions which impact Nektar Therapeutics's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NKTR.

What is Nektar Therapeutics's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, NKTR's PE ratio (Price to Earnings) is -1.05 and Price to Sales (PS) ratio is 3.2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NKTR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Nektar Therapeutics's stock?

In the past 10 years, Nektar Therapeutics has provided -0.177 (multiply by 100 for percentage) rate of return.